The biotechnology company is developing a first-in-class adjustable-dose gene therapy platform called Prometheusâ„¢, which can replace a broad range of multi-protein injection treatments with a single ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Remedium's lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a ...
NORWALK, Conn., Sept. 23, 2025 /PRNewswire/ -- Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Financing led by Lifespan Vision Ventures with ...
AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses The FGF18 gene therapy appears to induce chondrogenesis by ...
· Research focused on long-acting therapeutics based on Remedium's proprietary Prometheus platform · Multiple targets for the treatment of Obesity and Type 2 Diabetes BOSTON, MASSACHUSETTS / ACCESS ...
NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's ...
Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results